Gavilimomab

Gavilimomab
Monoclonal antibody
Type Whole antibody
Source Mouse
Target CD147
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
 ☒N☑Y (what is this?)  (verify)

Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]

It was originally developed by Abgenix,[1] which was later acquired by Amgen.

References

  1. 1 2 findarticles.com: Sangstat to Provide Clinical Development Update At JP Morgan H&Q Conference in San Francisco
  2. ↑ Macmillan, ML; Couriel, D; Weisdorf, DJ; Schwab, G; Havrilla, N; Fleming, TR; Huang, S; Roskos, L; et al. (Mar 2007). "A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease". Blood. 109 (6): 2657–62. doi:10.1182/blood-2006-08-013995. PMID 17110457.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.